bluuebunny/crossref_metadata_2025 huggingface dataset:
Table S4 from Mechanism-informed Repurposing of Minocycline Overcomes Resistance to Topoisomerase Inhibition for Peritoneal Carcinomatosis
Authors: Huang Huang-Chiao , Liu Joyce , Baglo Yan , Rizvi Imran , Anbil Sriram , Pigula Michael , Hasan Tayyaba
Published: April 2023

Preliminary analysis of costs related to the side effect management for irinotecan-based combination therapies.
Figure S2 from Distribution and Activity of Lenvatinib in Brain Tumor Models of Human Anaplastic Thyroid Cancer Cells in Severe Combined Immune Deficient Mice
Authors: Wang Rong , Yamada Tadaaki , Arai Sachiko , Fukuda Koji , Taniguchi Hirokazu , Tanimoto Azusa , Nishiyama Akihiro , Takeuchi Shinji , Yamashita Kaname , Ohtsubo Koshiro , Matsui Junji , Onoda Naoyoshi , Hirata Eishu , Taira Shu , Yano Seiji
Published: April 2023

Supplementary Figure 2 shows lenvatinib or sorafenib treatment is well-tolerated in ATC cell subcutaneous tumor and brain tumor models.
Figure S3 from Mechanism-informed Repurposing of Minocycline Overcomes Resistance to Topoisomerase Inhibition for Peritoneal Carcinomatosis
Authors: Huang Huang-Chiao , Liu Joyce , Baglo Yan , Rizvi Imran , Anbil Sriram , Pigula Michael , Hasan Tayyaba
Published: April 2023

The combination of minocycline and nanoliposomal irinotecan (nal-IRI) is tolerable by mice bearing human OVCAR-4 cells. Changes in mouse body weight were monitored longitudinally before and after treatment. The following treatments were given to mice at 7 days after subcutaneous OVCAR-4 (3 x 10^6 cells in 50% culture medium and 50% Matrigel) tumor implantation: (i) No-treatment (NT); (ii) Minocycline (Mn) (50 mg/kg was administered on day 7, which is followed by eight more cycles of Mn at 25 mg/kg body weight on the following days post-implantation: 8, 9, 10, 11, 14, 15, 17, 18; (iii) nal-IRI (nal-IRI; three doses at 5 mg/kg each, on days 11, 15, and 18); and (iv) Combination of Mn and nal-IRI. Recorded mouse weights were normalized to day 7 mouse weight (n = 3 - 13 mice per group). All changes in mouse weight were within 10% compared to the start of experiment, suggesting all treatments were tolerable by mice.
Figure S2 from Mechanism-informed Repurposing of Minocycline Overcomes Resistance to Topoisomerase Inhibition for Peritoneal Carcinomatosis
Authors: Huang Huang-Chiao , Liu Joyce , Baglo Yan , Rizvi Imran , Anbil Sriram , Pigula Michael , Hasan Tayyaba
Published: April 2023

Representative size distribution of nanoliposomal irinotecan (nal-IRI) and absorbance spectrum of nal-IRI in DMSO. (A) Mono-dispersed nal-IRI is approximately 115 nm in diameter with a Polydispersity index below 0.1. (B) Nal-IRI absorbance spectrum was measured in DMSO, and the irinotecan concentration was determined by UV-Vis spectroscopy with appropriate standard curves.
Table S3 from Pharmacological Dual Inhibition of Tumor and Tumor-Induced Functional Limitations in a Transgenic Model of Breast Cancer
Authors: Wang Ruizhong , Bhat-Nakshatri Poornima , Padua Maria B. , Prasad Mayuri S , Anjanappa Manjushree , Jacobson Max , Finnearty Courtney , Sefcsik Victoria , McElyea Kyle , Redmond Rachael , Sandusky George , Penthala Narsimha , Crooks Peter A , Liu Jianguo , Zimmers Teresa , Nakshatri Harikrishna
Published: April 2023

Results of cytokine array analyses of plasma samples
Supplementary Methods; Supplementary Figures S1-S4; and Supplementary Tables S1-S4 from The Increased Expression of Estrogen-Related Receptor α Correlates with Wnt5a and Poor Prognosis in Patients with Glioma
Authors: Zhang Liudi , Zhu Yingfeng , Cheng Haixia , Zhang Jinsen , Zhu Yuqian , Chen Haifei , Chen Lu , Qi Huijie , Ren Guoqiang , Tang Jianmin , Zhong Mingkang , Hua Wei , Shi Xiaojin , Li Qunyi
Published: April 2023

Supplementary Figure S1: ERRα expression was regulated by shERRα/lenti-ERRα in U87MG and U251; Supplementary Figure S2: There is a correlation between inhibition rates of XCT790 (5, 10 μM) and ERRα expression levels: Supplementary Figure S3: ERRα overexpression promoted the glioma cell growth in BrdU incorporation; Supplementary Figure S4: ERRα knockdown inhibited glioma growth in vivo; Table S1 shows pathological information of 107 glioma patients; Supplementary Table S2: ERRα expression was significantly high as the glioma pathological grade was increased; Table S3 shows the primer sequences of ERRα and wnt genes; Table S4 shows primers used for detecting putative ERREs.
Figure S4 from Mutual Influence of ROS, pH, and CLIC1 Membrane Protein in the Regulation of G1–S Phase Progression in Human Glioblastoma Stem Cells
Authors: Peretti Marta , Raciti Federica Maddalena , Carlini Valentina , Verduci Ivan , Sertic Sarah , Barozzi Sara , Garré Massimiliano , Pattarozzi Alessandra , Daga Antonio , Barbieri Federica , Costa Alex , Florio Tullio , Mazzanti Michele
Published: April 2023

Current density/voltage relationships of CLIC1 current in CSCs
Figure S2 from Mutual Influence of ROS, pH, and CLIC1 Membrane Protein in the Regulation of G1–S Phase Progression in Human Glioblastoma Stem Cells
Authors: Peretti Marta , Raciti Federica Maddalena , Carlini Valentina , Verduci Ivan , Sertic Sarah , Barozzi Sara , Garré Massimiliano , Pattarozzi Alessandra , Daga Antonio , Barbieri Federica , Costa Alex , Florio Tullio , Mazzanti Michele
Published: April 2023

CLIC1 silencing western blot.
Figure S4 from IL6 Receptor Blockade Enhances Chemotherapy Efficacy in Pancreatic Ductal Adenocarcinoma
Authors: Long Kristen B. , Tooker Graham , Tooker Evan , Luque Santiago Lombo , Lee Jae W. , Pan Xiaoqing , Beatty Gregory L.
Published: April 2023

Gating strategy for mouse PBMCs
Figure S2 from Novel Fluoroindenoisoquinoline Non-Camptothecin Topoisomerase I Inhibitors
Authors: Marzi Laetitia , Agama Keli , Murai Junko , Difilippantonio Simone , James Amy , Peer Cody J. , Figg William D. , Beck Daniel , Elsayed Mohamed S.A. , Cushman Mark , Pommier Yves
Published: April 2023

SLFN11 deletion conferes resistance to fluoroindenoisoquinolines LMP517, LMP135 and LMP134 and to topotecan in CCRF-CEM cells
Supplemental Info from Response and Resistance to Paradox-Breaking BRAF Inhibitor in Melanomas In Vivo and Ex Vivo
Authors: Hartsough Edward J. , Kugel Curtis H. , Vido Michael J. , Berger Adam C. , Purwin Timothy J. , Goldberg Allison , Davies Michael A. , Schiewer Matthew J. , Knudsen Karen E. , Bollag Gideon , Aplin Andrew E.
Published: April 2023

Supplemental Figure 1: PLX8394 does not alter CRAF or c-Src phosphorylation; Supplemental Figure 2. Treatment of xenograft-derived tumor pieces in an ex vivo explant system; Supplemental Figure 3: Patient sample extended data; Supplemental Figure 4: Parallel ex vivo dosing and homodimerization of vemurafenib and PLX8394 treatments; Supplemental Figure 5: PBRT characterization; Supplemental Figure 6: Targeting AKT and PDGFRβ in PBRT cell lines does not resensitize to PLX8394; Supplemental Figure 7: BRAF V600E splice variant analysis of PBRT cell lines and signaling and growth response of second-line therapies; Supplemental Methods.
Table S2 from A Potent Blood–Brain Barrier-Permeable Mutant IDH1 Inhibitor Suppresses the Growth of Glioblastoma with IDH1 Mutation in a Patient-Derived Orthotopic Xenograft Model
Authors: Machida Yukino , Nakagawa Makoto , Matsunaga Hironori , Yamaguchi Masayuki , Ogawara Yoko , Shima Yutaka , Yamagata Kazutsune , Katsumoto Takuo , Hattori Ayuna , Itoh Masato , Seki Takahiko , Nishiya Yumi , Nakamura Koichi , Suzuki Kanae , Imaoka Tomoki , Baba Daichi , Suzuki Makoto , Sampetrean Oltea , Saya Hideyuki , Ichimura Koichi , Kitabayashi Issay
Published: April 2023

Table S2 shows characteristics of two glioblastoma cells.
Figure S2 from A Potent Blood–Brain Barrier-Permeable Mutant IDH1 Inhibitor Suppresses the Growth of Glioblastoma with IDH1 Mutation in a Patient-Derived Orthotopic Xenograft Model
Authors: Machida Yukino , Nakagawa Makoto , Matsunaga Hironori , Yamaguchi Masayuki , Ogawara Yoko , Shima Yutaka , Yamagata Kazutsune , Katsumoto Takuo , Hattori Ayuna , Itoh Masato , Seki Takahiko , Nishiya Yumi , Nakamura Koichi , Suzuki Kanae , Imaoka Tomoki , Baba Daichi , Suzuki Makoto , Sampetrean Oltea , Saya Hideyuki , Ichimura Koichi , Kitabayashi Issay
Published: April 2023

DS-1001b demonstrates anti-neoplastic activity in IDH1 mutant glioblastoma xenografts.
Supplementary Tables 1-6 from Inhibition of the Replication Stress Response Is a Synthetic Vulnerability in SCLC That Acts Synergistically in Combination with Cisplatin
Authors: Nagel Remco , Avelar Ana Teresa , Aben Nanne , Proost Natalie , van de Ven Marieke , van der Vliet Jan , Cozijnsen Miranda , de Vries Hilda , Wessels Lodewyk F. A. , Berns Anton
Published: April 2023

Supplementary Table 1. Primers used for amplification of gRNA inserts. Supplementary Table 2. Raw and normalized read counts per sgRNA. Supplementary Table 3. Results from the MaGeCK analysis per gene. Supplementary Table 4. Individual genes belonging to the GO terms represented in Table 1. Supplementary Table 5. Dropouts functioning in the replication stress response. Supplementary Table 6. Expression values of the human SCLC and NSCLC cell lines. Values represent 2log(cpm) from next generation sequencing data from Iori et al., 2016.
Figure S4 from Phosphodiesterase 3A Represents a Therapeutic Target that Drives Stem Cell–like Property and Metastasis in Breast Cancer
Authors: Hao Na , Shen Wenzhi , Du Renle , Jiang Shan , Zhu Junyong , Chen Yanan , Huang Chongbiao , Shi Yi , Xiang Rong , Luo Yunping
Published: April 2023

Figure S4 shows the relationship between PDE3A and CCDC88A.
Figure S3 from Phosphodiesterase 3A Represents a Therapeutic Target that Drives Stem Cell–like Property and Metastasis in Breast Cancer
Authors: Hao Na , Shen Wenzhi , Du Renle , Jiang Shan , Zhu Junyong , Chen Yanan , Huang Chongbiao , Shi Yi , Xiang Rong , Luo Yunping
Published: April 2023

Figure S3 shows PDE3A was increased in stem cell properties and metastasis in breast cancer model.
Supplementary Tables 1-4 and Supplementary Figures S1 to S7; and Supplementary Materials and Methods from β-Arrestins Regulate Stem Cell-Like Phenotype and Response to Chemotherapy in Bladder Cancer
Authors: Kallifatidis Georgios , Smith Diandra K. , Morera Daley S. , Gao Jie , Hennig Martin J. , Hoy James J. , Pearce Richard F. , Dabke Isha R. , Li Jiemin , Merseburger Axel S. , Kuczyk Markus A. , Lokeshwar Vinata B. , Lokeshwar Bal L.
Published: April 2023

Supplementary Table S1: Specimen and patient characteristics; Supplementary Table S2: Determination of the association between adjuvant treatment failure and demographic/clinical parameters or marker levels; Supplementary Table S3: qPCR primers and ARRB1-specific CRISPR guide RNA sequences; Supplementary Table S4: Source of various antibodies used for immunofluorescence and Western blotting; Supplementary Figure S1: Kaplan Meier plot for stratification of patients into higher risk and lower risk for Disease-Specific Mortality (DSM) based on the ARRB2 arrestin level; Supplementary Figure S2: Expression of cytokeratins and Bmi-1 following modulation of ARRB2 levels in 5637 cells; Supplementary Figure S3: Expression of SOX2 following modulation of ARRB2 levels in bladder cancer cell lines; Supplementary Figure S4: Response of ARRB2 overexpressing transfectants to Cisplatin; Supplementary Figure S5: Expression ABC transporters in ARRB2-modulated bladder cancer cells; Supplementary Figure S6: Effect of ARRB2 overexpression on Cancer Stem Cell markers in vivo; Supplementary Figure S7: ARRB1 depletion affects clonogenic growth, spheroid formation and expression of CSC markers
Supplementary Figure 5 from Therapeutic Targeting of KDM1A/LSD1 in Ewing Sarcoma with SP-2509 Engages the Endoplasmic Reticulum Stress Response
Authors: Pishas Kathleen I. , Drenberg Christina D. , Taslim Cenny , Theisen Emily R. , Johnson Kirsten M. , Saund Ranajeet S. , Pop Ioana L. , Crompton Brian D. , Lawlor Elizabeth R. , Tirode Franck , Mora Jaume , Delattre Olivier , Beckerle Mary C. , Callen David F. , Sharma Sunil , Lessnick Stephen L.
Published: April 2023

Hypersensitive SP-2509 cell lines display similar transcriptomic profiles
Supplementary Figure 4 from Therapeutic Targeting of KDM1A/LSD1 in Ewing Sarcoma with SP-2509 Engages the Endoplasmic Reticulum Stress Response
Authors: Pishas Kathleen I. , Drenberg Christina D. , Taslim Cenny , Theisen Emily R. , Johnson Kirsten M. , Saund Ranajeet S. , Pop Ioana L. , Crompton Brian D. , Lawlor Elizabeth R. , Tirode Franck , Mora Jaume , Delattre Olivier , Beckerle Mary C. , Callen David F. , Sharma Sunil , Lessnick Stephen L.
Published: April 2023

GSK-LSD1, Doxorubicin and AraC have no effect on KDM1A and KDM1B expression
Supplemental Table 1 from Co-targeting HGF/cMET Signaling with MEK Inhibitors in Metastatic Uveal Melanoma
Authors: Cheng Hanyin , Chua Vivian , Liao Connie , Purwin Timothy J. , Terai Mizue , Kageyama Ken , Davies Michael A. , Sato Takami , Aplin Andrew E.
Published: April 2023

Supplemental Table 1: Patient characteristics and treatment history.
Supplemental Figure Legends from Co-targeting HGF/cMET Signaling with MEK Inhibitors in Metastatic Uveal Melanoma
Authors: Cheng Hanyin , Chua Vivian , Liao Connie , Purwin Timothy J. , Terai Mizue , Kageyama Ken , Davies Michael A. , Sato Takami , Aplin Andrew E.
Published: April 2023

Supplemental Figure 1 to 5 legends
Supplementary Table S2 from Transcription Factor SOX18 Promotes Clear Cell Renal Cell Carcinoma Progression and Alleviates Cabozantinib-Mediated Inhibitory Effects
Authors: Huaqi Yin , Caipeng Qin , Qiang Wang , Yiqing Du , Xiang Dai , Xu Tang , Xiaowei Zhang , Qing Li , Shijun Liu , Tao Xu
Published: April 2023

Information of antibodies used in the present study
Supplementary Figures S1-S5 from Transcription Factor SOX18 Promotes Clear Cell Renal Cell Carcinoma Progression and Alleviates Cabozantinib-Mediated Inhibitory Effects
Authors: Huaqi Yin , Caipeng Qin , Qiang Wang , Yiqing Du , Xiang Dai , Xu Tang , Xiaowei Zhang , Qing Li , Shijun Liu , Tao Xu
Published: April 2023

Figure S1 shows the role of SOX18 on ccRCC cell growth. Figure S2 shows the analysis of RNA-seq and the effect of SOX18 on protein expression and cell apoptosis. Figure S3 shows the effect of SOX18 on cell migration and invasion, and the expression of other proteins. Figure S4 shows the influence of SOX18 on cabozantinib-mediated inhibitory effect on cellular function. Figure S5 shows the influence of SOX18 knockdown on cell migration and invasion under cabozantinib.
Supplementary materials and methods and legends for Supplementary Figures and Tables from Impact of Chemical-Induced Mutational Load Increase on Immune Checkpoint Therapy in Poorly Responsive Murine Tumors
Authors: Kuczynski Elizabeth A. , Krueger Janna , Chow Annabelle , Xu Ping , Man Shan , Sundaravadanam Yogi , Miller Jessica K. , Krzyzanowski Paul M. , Kerbel Robert S.
Published: April 2023

Supplementary materials and methods and legends for Supplementary Figures and Tables
Supplementary Tables S1-S4 from Impact of Chemical-Induced Mutational Load Increase on Immune Checkpoint Therapy in Poorly Responsive Murine Tumors
Authors: Kuczynski Elizabeth A. , Krueger Janna , Chow Annabelle , Xu Ping , Man Shan , Sundaravadanam Yogi , Miller Jessica K. , Krzyzanowski Paul M. , Kerbel Robert S.
Published: April 2023

Supplementary Table S1 lists missense mutations in mutagenized EMT-6/P variant cells. Supplementary Table S2 lists driver mutations in mutagenized EMT-6/P variant cells. Supplementary Table S3 lists the results of functional annotation clustering of mutagenized EMT-6/P variants. Supplementary Table S4 tabulates numerically growth rates of mutagenized variants in syngeneic and immunodeficient mice.
Supplementary Figures from Impact of Chemical-Induced Mutational Load Increase on Immune Checkpoint Therapy in Poorly Responsive Murine Tumors
Authors: Kuczynski Elizabeth A. , Krueger Janna , Chow Annabelle , Xu Ping , Man Shan , Sundaravadanam Yogi , Miller Jessica K. , Krzyzanowski Paul M. , Kerbel Robert S.
Published: April 2023

Supplementary Figure S1 shows the gating strategy used to identify tumor-infiltrating immune cells. Supplementary Figure S2 shows in vitro survival and viability of tumor cell variants following mutagen treatment and after their recovery, as well as morphologic characteristics of some variants. Supplementary Figure S3 shows the doubling time of mutagenized and control tumors in syngeneic mice and the acquired mutations in mutagenized RENCA cells. Supplementary Figure S4 shows additional tumor growth curves of mutagenized variants in response to PD-L1 blockade. Supplementary Figure S5 shows PD-1, PD-L1 and MHC-I expression on immune and/or mutagenized tumor cells and CD8+ T cell distribution in tumors. Supplementary Figure S6 shows the mutational signature induced by cisplatin and cyclophosphamide in EMT-6 tumor cells.
Figures S1-S4 and Tables S1-S2 from Preclinical Development of U3-1784, a Novel FGFR4 Antibody Against Cancer, and Avoidance of Its On-target Toxicity
Authors: Bartz René , Fukuchi Keisuke , Ohtsuka Toshiaki , Lange Tanja , Gruner Katrin , Watanabe Ichiro , Hayashi Shinko , Oda Yoko , Kawaida Reimi , Komori Hironobu , Kashimoto Yoshinori , Wirtz Peter , Mayer Jan-Peter A. , Redondo-Müller Mauricio , Saito Shuntaro , Takahashi Mizuki , Hanzawa Hiroyuki , Imai Emi , Martinez Alberto , Hanai Masaharu , Häussinger Dieter , Chapman Roger W. , Agatsuma Toshinori , Bange Johannes , Abraham Reimar
Published: April 2023

Figures S1-S4 depicting antibody purification and binding, serum chemistry at 10 mg/kg antibody and expression of bile acid transporters; Tables S1-S2 show CRO's that preformed in vivo experiments and primers for quantitative RT-PCR
Supplementary Figure 4 from Altered Steroid Milieu in AI-Resistant Breast Cancer Facilitates AR Mediated Gene-Expression Associated with Poor Response to Therapy
Authors: Creevey Laura , Bleach Rachel , Madden Stephen F. , Toomey Sinead , Bane Fiona T. , Varešlija Damir , Hill Arnold D. , Young Leonie S. , McIlroy Marie
Published: April 2023

AR and ER binding events in the proximal promoters of SGK3, MYBL1, GREB1 and PKIB.
Supplemental Tables from Altered Steroid Milieu in AI-Resistant Breast Cancer Facilitates AR Mediated Gene-Expression Associated with Poor Response to Therapy
Authors: Creevey Laura , Bleach Rachel , Madden Stephen F. , Toomey Sinead , Bane Fiona T. , Varešlija Damir , Hill Arnold D. , Young Leonie S. , McIlroy Marie
Published: April 2023

Supplemental tables 1& 2
Supplementary Material from A Tricin Derivative from Deschampsia antarctica Desv. Inhibits Colorectal Carcinoma Growth and Liver Metastasis through the Induction of a Specific Immune Response
Authors: Malvicini Mariana , Gutierrez-Moraga Ana , Rodriguez Marcelo M. , Gomez-Bustillo Sofia , Salazar Lorena , Sunkel Carlos , Nozal Leonor , Salgado Antonio , Hidalgo Manuel , Lopez-Casas Pedro P. , Novella Jose Luis , Vaquero Juan Jose , Alvarez-Builla Julio , Mora Adda , Gidekel Manuel , Mazzolini Guillermo
Published: April 2023

Information about experimental procedure to obtain Antartina
Supplementary Figure 2 from A Tricin Derivative from Deschampsia antarctica Desv. Inhibits Colorectal Carcinoma Growth and Liver Metastasis through the Induction of a Specific Immune Response
Authors: Malvicini Mariana , Gutierrez-Moraga Ana , Rodriguez Marcelo M. , Gomez-Bustillo Sofia , Salazar Lorena , Sunkel Carlos , Nozal Leonor , Salgado Antonio , Hidalgo Manuel , Lopez-Casas Pedro P. , Novella Jose Luis , Vaquero Juan Jose , Alvarez-Builla Julio , Mora Adda , Gidekel Manuel , Mazzolini Guillermo
Published: April 2023

Preconditioning of DCs derived from (A) cancer patients and healthy donors, and (B) mice using10 μg/ml Antartina{trade mark, serif} enhances the expression of activation markers
Supplementary Table S3 from In Vitro and In Vivo Synergistic Antitumor Activity of the Combination of BKM120 and Erlotinib in Head and Neck Cancer: Mechanism of Apoptosis and Resistance
Authors: Anisuzzaman Abu Syed Md , Haque Abedul , Wang Dongsheng , Rahman Mohammad Aminur , Zhang Chao , Chen Zhengjia , Chen Zhuo Georgia , Shin Dong M. , Amin A.R.M. Ruhul
Published: April 2023

Supplementary Table S3: IC50 values for BKM120 and Erlotinib at 72 h
Supplementary Table S1 from In Vitro and In Vivo Synergistic Antitumor Activity of the Combination of BKM120 and Erlotinib in Head and Neck Cancer: Mechanism of Apoptosis and Resistance
Authors: Anisuzzaman Abu Syed Md , Haque Abedul , Wang Dongsheng , Rahman Mohammad Aminur , Zhang Chao , Chen Zhengjia , Chen Zhuo Georgia , Shin Dong M. , Amin A.R.M. Ruhul
Published: April 2023

Supplementary Table S1: Characteristics of Cell Lines Used
Supplementary Movie S3 from Targeting TAO Kinases Using a New Inhibitor Compound Delays Mitosis and Induces Mitotic Cell Death in Centrosome Amplified Breast Cancer Cells
Authors: Koo Chuay-Yeng , Giacomini Caterina , Reyes-Corral Marta , Olmos Yolanda , Tavares Ignatius A. , Marson Charles M. , Linardopoulos Spiros , Tutt Andrew N. , Morris Jonathan D.H.
Published: April 2023

Live images of growing SKBR3 cells. Representative time-lapse video images showing GFP-α-tubulin expressing SKBR3 cells incubated in growth medium containing equivalent DMSO (0.05%) for 48 hours.
Supporting Video 11 from Is the Fate of Clinical Candidate Arry-520 Already Sealed? Predicting Resistance in Eg5–Inhibitor Complexes
Authors: Indorato Rose-Laure , Talapatra Sandeep K. , Lin Fangzhu , Haider Shozeb , Mackay Simon P. , Kozielski Frank , Skoufias Dimitrios A.
Published: April 2023

Molecular dynamics simulations of the Eg5(D130A)-Arry-520 complex.
Supporting Video 09 from Is the Fate of Clinical Candidate Arry-520 Already Sealed? Predicting Resistance in Eg5–Inhibitor Complexes
Authors: Indorato Rose-Laure , Talapatra Sandeep K. , Lin Fangzhu , Haider Shozeb , Mackay Simon P. , Kozielski Frank , Skoufias Dimitrios A.
Published: April 2023

Molecular dynamics simulations of the Eg5(L214A)-Arry-520 complex.
Supporting Video 08 from Is the Fate of Clinical Candidate Arry-520 Already Sealed? Predicting Resistance in Eg5–Inhibitor Complexes
Authors: Indorato Rose-Laure , Talapatra Sandeep K. , Lin Fangzhu , Haider Shozeb , Mackay Simon P. , Kozielski Frank , Skoufias Dimitrios A.
Published: April 2023

Molecular dynamics simulations of the wild type Eg5-ispinesib complex.
Supporting Video 05 from Is the Fate of Clinical Candidate Arry-520 Already Sealed? Predicting Resistance in Eg5–Inhibitor Complexes
Authors: Indorato Rose-Laure , Talapatra Sandeep K. , Lin Fangzhu , Haider Shozeb , Mackay Simon P. , Kozielski Frank , Skoufias Dimitrios A.
Published: April 2023

Time lapse imaging of U2OS-Eg5(D130A) expressing cells exposed to 10 nM ispinesib and followed for 16h. Cells divide uninhibited.
Supporting Video 01 from Is the Fate of Clinical Candidate Arry-520 Already Sealed? Predicting Resistance in Eg5–Inhibitor Complexes
Authors: Indorato Rose-Laure , Talapatra Sandeep K. , Lin Fangzhu , Haider Shozeb , Mackay Simon P. , Kozielski Frank , Skoufias Dimitrios A.
Published: April 2023

Time lapse imaging of untreated U2OS cells followed for 16h. Cells divide normally.
Supplemental Figure 3 from Interleukin-24 (IL24) Is Suppressed by PAX3-FOXO1 and Is a Novel Therapy for Rhabdomyosarcoma
Authors: Lacey Alexandra , Hedrick Erik , Cheng Yating , Mohankumar Kumaravel , Warren Melanie , Safe Stephen
Published: April 2023

The effects of transfection of ARMS cells with siIL24
Supplementary Table 1 and Supplementary Figures 1-3 from Is the Fate of Clinical Candidate Arry-520 Already Sealed? Predicting Resistance in Eg5–Inhibitor Complexes
Authors: Indorato Rose-Laure , Talapatra Sandeep K. , Lin Fangzhu , Haider Shozeb , Mackay Simon P. , Kozielski Frank , Skoufias Dimitrios A.
Published: April 2023

Table S1: Crystallographic table of data corresponding to the Eg5-Arry-520 complexes. Figure S1: Interactions of the inhibitor and conformational changes upon inhibitor binding. Figure S2: Surface representation of the allosteric inhibitor-binding pocket of wild type Eg5 bound to either Arry-520 or ispinesib. Figure S3: Monitored distances between the Glu116-Arg221 ion pair in the Eg5 bound to Arry-520 and Root mean square fluctuations of the Eg5(WT), Eg5(D130A), Eg5(L214A) motor domain bound to either Arry-520 or ispinesib.
Supplemental Figure 2 from Interleukin-24 (IL24) Is Suppressed by PAX3-FOXO1 and Is a Novel Therapy for Rhabdomyosarcoma
Authors: Lacey Alexandra , Hedrick Erik , Cheng Yating , Mohankumar Kumaravel , Warren Melanie , Safe Stephen
Published: April 2023

Immunostaining of Rh30 and Rh18 cells after transfection with pCMV-6-IL-24
Supplementary Materials from Acquired Resistance to the Hsp90 Inhibitor, Ganetespib, in KRAS-Mutant NSCLC Is Mediated via Reactivation of the ERK–p90RSK–mTOR Signaling Network
Authors: Chatterjee Suman , Huang Eric H.-B. , Christie Ian , Kurland Brenda F. , Burns Timothy F.
Published: April 2023

Supplementary figure legends and tables
Table S1: IC50 (nM) for M cells deleted PSMC subunits treated with BTZ from CRISPR Genome-Wide Screening Identifies Dependence on the Proteasome Subunit PSMC6 for Bortezomib Sensitivity in Multiple Myeloma
Authors: Shi Chang-Xin , Kortüm K. Martin , Zhu Yuan Xiao , Bruins Laura A. , Jedlowski Patrick , Votruba Patrick G. , Luo Moulun , Stewart Robert A. , Ahmann Jonathan , Braggio Esteban , Stewart A. Keith
Published: April 2023

IC50 (nM) for M cells deleted PSMC subunits treated with BTZ
Supplement 5. A total of 36 mutations in 19S proteasome subunits out of 895 patients were identified in CoMMpass study. from CRISPR Genome-Wide Screening Identifies Dependence on the Proteasome Subunit PSMC6 for Bortezomib Sensitivity in Multiple Myeloma
Authors: Shi Chang-Xin , Kortüm K. Martin , Zhu Yuan Xiao , Bruins Laura A. , Jedlowski Patrick , Votruba Patrick G. , Luo Moulun , Stewart Robert A. , Ahmann Jonathan , Braggio Esteban , Stewart A. Keith
Published: April 2023

The mutation profile of all proteasome subunits in the genomic sequences derived by whole exome sequencing of 895 patients in the IA10 release of the CoMMpass study (https://www.themmrf.org/). A total of 36 mutations in 19S proteasome subunits were identified (one patient has three PSMC5 mutations and one patient has two PSMD7 mutations).A total of 16 PSMC subunit mutations, were identified although none of them was in PSMC6.
Supplementary Data from Co-targeting Bulk Tumor and CSCs in Clinically Translatable TNBC Patient-Derived Xenografts via Combination Nanotherapy
Authors: Sulaiman Andrew , McGarry Sarah , El-Sahli Sara , Li Li , Chambers Jason , Phan Alexandra , Côté Marceline , Cron Greg O. , Alain Tommy , Le Yevgeniya , Lee Seung-Hwan , Liu Sheng , Figeys Daniel , Gadde Suresh , Wang Lisheng
Published: April 2023

Supplementary figures S1-S9
Supplement 3. sgRNA sequences used for second round screen. from CRISPR Genome-Wide Screening Identifies Dependence on the Proteasome Subunit PSMC6 for Bortezomib Sensitivity in Multiple Myeloma
Authors: Shi Chang-Xin , Kortüm K. Martin , Zhu Yuan Xiao , Bruins Laura A. , Jedlowski Patrick , Votruba Patrick G. , Luo Moulun , Stewart Robert A. , Ahmann Jonathan , Braggio Esteban , Stewart A. Keith
Published: April 2023

The 31 most abundant of these sgRNAs found in cells surviving BTZ treatment were selected for secondary screening (Figure 2B). Each of the 31 potential BTZ resistance inducing genes was targeted by four sgRNAs, including three sgRNAs from the GeCKO V2 library A and the fourth from GeCKO V2 library B.
Supplementary Figure S1 from Preclinical Activity of Abemaciclib Alone or in Combination with Antimitotic and Targeted Therapies in Breast Cancer
Authors: O'Brien Neil , Conklin Dylan , Beckmann Richard , Luo Tong , Chau Kevin , Thomas Josh , Mc Nulty Ann , Marchal Christophe , Kalous Ondrej , von Euw Erika , Hurvitz Sara , Mockbee Colleen , Slamon Dennis J.
Published: April 2023

Abemaciclib induces cell cycle arrest but not cell death in Rb-intact breast cancer cell lines
Figure S6 from Cyclooxygenase-2 Influences Response to Cotargeting of MEK and CDK4/6 in a Subpopulation of Pancreatic Cancers
Authors: Maust Joel D. , Frankowski-McGregor Christy L. , Bankhead Armand , Simeone Diane M. , Sebolt-Leopold Judith S.
Published: April 2023

COX-2 expression at the RNA and protein levels
Supporting Information from Evaluation of Nonpeptidic Ligand Conjugates for the Treatment of Hypoxic and Carbonic Anhydrase IX–Expressing Cancers
Authors: Lv Peng-Cheng , Roy Jyoti , Putt Karson S. , Low Philip S.
Published: April 2023

SI Figure1.Statistical differences between CA IX-PEG12-EC20 and competition group tissue biodistribution; SI Figure 2. Statistical differences of tumor volume and % weight change in IP injected mice; SI Figure 3. Statistical differences of tumor volume and % weight change in IV injected mice.
Figure S4 from Cyclooxygenase-2 Influences Response to Cotargeting of MEK and CDK4/6 in a Subpopulation of Pancreatic Cancers
Authors: Maust Joel D. , Frankowski-McGregor Christy L. , Bankhead Armand , Simeone Diane M. , Sebolt-Leopold Judith S.
Published: April 2023

Effect of combination treatment on COX-2 and Pdcd4 expression
Figure S2 from Cyclooxygenase-2 Influences Response to Cotargeting of MEK and CDK4/6 in a Subpopulation of Pancreatic Cancers
Authors: Maust Joel D. , Frankowski-McGregor Christy L. , Bankhead Armand , Simeone Diane M. , Sebolt-Leopold Judith S.
Published: April 2023

Effect of combination treatment on growth and protein expression in models eliciting high and low synergy scores
Supplementary table S1 from Aggressive Progression in Glioblastoma Cells through Potentiated Activation of Integrin α5β1 by the Tenascin-C–Derived Peptide TNIIIA2
Authors: Fujita Motomichi , Yamamoto Tetsuya , Iyoda Takuya , Fujisawa Tatsuya , Sasada Manabu , Nagai Reo , Kudo Chikako , Otsuka Kazuki , Kamiya Sadahiro , Kodama Hiroaki , Fukai Fumio
Published: April 2023

Antibody information
Supplementary Figure 5 from Dimethyl Fumarate Controls the NRF2/DJ-1 Axis in Cancer Cells: Therapeutic Applications
Authors: Saidu Nathaniel Edward Bennett , Noé Gaëlle , Cerles Olivier , Cabel Luc , Kavian-Tessler Niloufar , Chouzenoux Sandrine , Bahuaud Mathilde , Chéreau Christiane , Nicco Carole , Leroy Karen , Borghese Bruno , Goldwasser François , Batteux Frédéric , Alexandre Jérôme
Published: April 2023

Modulation of DMF-induced cell death by DJ1 levels in OVCAR3 cells.
Supplementary Figure 4 from Dimethyl Fumarate Controls the NRF2/DJ-1 Axis in Cancer Cells: Therapeutic Applications
Authors: Saidu Nathaniel Edward Bennett , Noé Gaëlle , Cerles Olivier , Cabel Luc , Kavian-Tessler Niloufar , Chouzenoux Sandrine , Bahuaud Mathilde , Chéreau Christiane , Nicco Carole , Leroy Karen , Borghese Bruno , Goldwasser François , Batteux Frédéric , Alexandre Jérôme
Published: April 2023

Immunoblots showing the effect of DMF on NRF2 along with its associated proteins in various cancer cells.
Supplementary Figure S3 from Eribulin Suppresses Clear Cell Sarcoma Growth by Inhibiting Cell Proliferation and Inducing Melanocytic Differentiation Both Directly and Via Vascular Remodeling
Authors: Nakai Sho , Tamiya Hironari , Imura Yoshinori , Nakai Takaaki , Yasuda Naohiro , Wakamatsu Toru , Tanaka Takaaki , Outani Hidetatsu , Takenaka Satoshi , Hamada Kenichiro , Myoui Akira , Araki Nobuhito , Ueda Takafumi , Yoshikawa Hideki , Naka Norifumi
Published: April 2023

Supplementary Figure S3 shows western blot in Hewga-CCS and MP-CCS-SY cells treated with CoCl2 in the absence or presence of SCH772984, and qRT-PCR in both CCS cells treated with CoCl2.
Supplementary figures and tables from Combined Inhibition of mTOR and CDK4/6 Is Required for Optimal Blockade of E2F Function and Long-term Growth Inhibition in Estrogen Receptor–positive Breast Cancer
Authors: Michaloglou Chrysiis , Crafter Claire , Siersbaek Rasmus , Delpuech Oona , Curwen Jon O. , Carnevalli Larissa S. , Staniszewska Anna D. , Polanska Urszula M. , Cheraghchi-Bashi Azadeh , Lawson Mandy , Chernukhin Igor , McEwen Robert , Carroll Jason S. , Cosulich Sabina C.
Published: April 2023

Supplementary Figure S1. Vistusertib (AZD2014) causes a decrease in RB phosphorylation in the absence of cell cycle arrest. Supplementary Figure S2. Different mTOR inhibitors in combination with palbociclib cause a decrease in cell viability. Supplementary Figure S3. The effects of vistusertib and palbociclib in the CTC-174 model in vivo. Supplementary Figure S4. Analysis of cell cycle and cell morphology. Supplementary Figure S5. The effects of vistusertib (AZD2014) and palbociclib on P21 expression levels. Supplementary Figure S6. Analysis of apoptosis in vitro and in vivo. Supplementary Figure S7. Robust inhibition of mTOR signalling by short-term treatment with RAD001 or vistusertib (AZD2014) does not affect ER binding. Supplementary Table S1. Selected genes and primer IDs. Supplementary Table S2. Supplementary Table S3. Palbociclib resistant cell lines are sensitive to vistusertib (AZD2014).
Supplemental figure legends from Sphingosine-1-Phosphate Receptor-1 Promotes Environment-Mediated and Acquired Chemoresistance
Authors: Lifshitz Veronica , Priceman Saul J. , Li Wenzhao , Cherryholmes Gregory , Lee Heehyoung , Makovski-Silverstein Adar , Borriello Lucia , DeClerck Yves A. , Yu Hua
Published: April 2023

Supplemental Figure 1. Bone marrow stromal cells enhance NB resistance to etoposide; Supplemental Figure 2. Overexpression of S1PR1 in CHLA-171 cells activates STAT3 and renders cells resistant to etoposide via JAK2/STAT3 signaling; Supplemental Figure 3. Elevated S1PR1 expression and STAT3 activation in etoposide-resistant CHLA-171 NB cells; Supplemental Figure 4. Taxol and JAK inhibitor effects on NB drug resistance; Supplemental Figure 5. Stattic and W146 inhibit STAT3 phosphorylation in NB drug resistant cells; Supplemental Figure 6. Crosstalk between NB cells and BM-MSC cells upregulates Sphk1.
Figure S1 from Preclinical Efficacy and Safety Comparison of CD3 Bispecific and ADC Modalities Targeting BCMA for the Treatment of Multiple Myeloma
Authors: Panowski Siler H. , Kuo Tracy C. , Zhang Yi , Chen Amy , Geng Tao , Aschenbrenner Laura , Kamperschroer Cris , Pascua Edward , Chen Wei , Delaria Kathy , Farias Santiago , Bateman Marjorie , Dushin Russell G. , Chin Sherman M. , Van Blarcom Thomas J. , Yeung Yik Andy , Lindquist Kevin C. , Chunyk Allison G. , Kuang Bing , Han Bora , Mirsky Michael , Pardo Ingrid , Buetow Bernard , Martin Thomas G. , Wolf Jeffrey L. , Shelton David , Rajpal Arvind , Strop Pavel , Chaparro-Riggers Javier , Sasu Barbra J.
Published: April 2023

ADC in vitro activity
Table S5 S6: TRA2A expression was significantly associated with poorer survival from TRA2A Promoted Paclitaxel Resistance and Tumor Progression in Triple-Negative Breast Cancers via Regulating Alternative Splicing
Authors: Liu Tieju , Sun Huizhi , Zhu Dongwang , Dong Xueyi , Liu Fang , Liang Xiaohui , Chen Chen , Shao Bing , Wang Meili , Wang Yi , Sun Baocun
Published: April 2023

Supplementary Table 5 and 6: TRA2A expression was significantly associated with poorer survival
Figure S6 from A Novel Theranostic Strategy for MMP-14–Expressing Glioblastomas Impacts Survival
Authors: Mohanty Suchismita , Chen Zixin , Li Kai , Morais Goreti Ribeiro , Klockow Jessica , Yerneni Ketan , Pisani Laura , Chin Frederick T. , Mitra Siddharta , Cheshier Samuel , Chang Edwin , Gambhir Sanjiv Sam , Rao Jianghong , Loadman Paul M. , Falconer Robert A. , Daldrup-Link Heike E.
Published: April 2023

Biodistribution and toxicity data from CLIO-ICT-treated mice
Figure S1 from A Novel Theranostic Strategy for MMP-14–Expressing Glioblastomas Impacts Survival
Authors: Mohanty Suchismita , Chen Zixin , Li Kai , Morais Goreti Ribeiro , Klockow Jessica , Yerneni Ketan , Pisani Laura , Chin Frederick T. , Mitra Siddharta , Cheshier Samuel , Chang Edwin , Gambhir Sanjiv Sam , Rao Jianghong , Loadman Paul M. , Falconer Robert A. , Daldrup-Link Heike E.
Published: April 2023

CLIO-ICTs induce apoptosis in GBM
methods_8.pdf from A Novel Anti-HER2 Antibody–Drug Conjugate XMT-1522 for HER2-Positive Breast and Gastric Cancers Resistant to Trastuzumab Emtansine
Authors: Le Joncour Vadim , Martins Ana , Puhka Maija , Isola Jorma , Salmikangas Marko , Laakkonen Pirjo , Joensuu Heikki , Barok Mark
Published: April 2023

methods_8.pdf from A Novel Anti-HER2 Antibody–Drug Conjugate XMT-1522 for HER2-Positive Breast and Gastric Cancers Resistant to Trastuzumab Emtansine
Supplementary Data from A Novel Anti-HER2 Antibody–Drug Conjugate XMT-1522 for HER2-Positive Breast and Gastric Cancers Resistant to Trastuzumab Emtansine
Authors: Le Joncour Vadim , Martins Ana , Puhka Maija , Isola Jorma , Salmikangas Marko , Laakkonen Pirjo , Joensuu Heikki , Barok Mark
Published: April 2023

Supplementary figures and figure legends
Table S4 from Anti-PSMA/CD3 Bispecific Antibody Delivery and Antitumor Activity Using a Polymeric Depot Formulation
Authors: Leconet Wilhem , Liu He , Guo Ming , Le Lamer-Déchamps Sophie , Molinier Charlotte , Kim Sae , Vrlinic Tjasa , Oster Murielle , Liu Fang , Navarro Vicente , Batra Jaspreet S. , Noriega Adolfo Lopez , Grizot Sylvestre , Bander Neil H.
Published: April 2023

Mean pharmacokinetics parameters of BiJ591
Table S2 from Anti-PSMA/CD3 Bispecific Antibody Delivery and Antitumor Activity Using a Polymeric Depot Formulation
Authors: Leconet Wilhem , Liu He , Guo Ming , Le Lamer-Déchamps Sophie , Molinier Charlotte , Kim Sae , Vrlinic Tjasa , Oster Murielle , Liu Fang , Navarro Vicente , Batra Jaspreet S. , Noriega Adolfo Lopez , Grizot Sylvestre , Bander Neil H.
Published: April 2023

Copolymers composition details
Supplementary Table 1 from Mechanisms of NT5C2-Mediated Thiopurine Resistance in Acute Lymphoblastic Leukemia
Authors: Moriyama Takaya , Liu Shuguang , Li Jing , Meyer Julia , Zhao Xujie , Yang Wentao , Shao Youming , Heath Richard , Hnízda Aleš , Carroll William L. , Yang Jun J.
Published: April 2023

This supplementary table describes metabolite levels and statistics from metabolite experiments
Supplementary Figures 1-5 from Mechanisms of NT5C2-Mediated Thiopurine Resistance in Acute Lymphoblastic Leukemia
Authors: Moriyama Takaya , Liu Shuguang , Li Jing , Meyer Julia , Zhao Xujie , Yang Wentao , Shao Youming , Heath Richard , Hnízda Aleš , Carroll William L. , Yang Jun J.
Published: April 2023

Supplementary figure 1 and 2 describe protein purity and expression. Supplementary Figure 3 shows cell-based cytotoxic assays. Supplementary Figure 4 shows protein activity against several substrates. Supplementary Figure 5 describes levels of individual metabolites.
Supplementary Data from Inhibition of AKT Sensitizes Cancer Cells to Antineoplastic Drugs by Downregulating Flap Endonuclease 1
Authors: Zhu Hong , Wu Congye , Wu Ting , Xia Wen , Ci Shusheng , He Weiru , Zhang Yilan , Li Lulu , Zhou Shiying , Zhang Jing , Edick Ashlin M. , Zhang Anna , Pan Fei-Yan , Hu Zhigang , He Lingfeng , Guo Zhigang
Published: April 2023

Figure S1-S5
Table S1 from Cooperative Effect of Oncogenic MET and PIK3CA in an HGF-Dominant Environment in Breast Cancer
Authors: Liu Shuying , Li Shunqiang , Wang Bailiang , Liu Wenbin , Gagea Mihai , Chen Huiqin , Sohn Joohyuk , Parinyanitikul Napa , Primeau Tina , Do Kim-Anh , Vande Woude George F. , Mendelsohn John , Ueno Naoto T. , Mills Gordon B. , Tripathy Debu , Gonzalez-Angulo Ana M.
Published: April 2023

Antibody list
Figure S5A from Cooperative Effect of Oncogenic MET and PIK3CA in an HGF-Dominant Environment in Breast Cancer
Authors: Liu Shuying , Li Shunqiang , Wang Bailiang , Liu Wenbin , Gagea Mihai , Chen Huiqin , Sohn Joohyuk , Parinyanitikul Napa , Primeau Tina , Do Kim-Anh , Vande Woude George F. , Mendelsohn John , Ueno Naoto T. , Mills Gordon B. , Tripathy Debu , Gonzalez-Angulo Ana M.
Published: April 2023

Effect of HGF on cell signaling
Figure S4 from Cooperative Effect of Oncogenic MET and PIK3CA in an HGF-Dominant Environment in Breast Cancer
Authors: Liu Shuying , Li Shunqiang , Wang Bailiang , Liu Wenbin , Gagea Mihai , Chen Huiqin , Sohn Joohyuk , Parinyanitikul Napa , Primeau Tina , Do Kim-Anh , Vande Woude George F. , Mendelsohn John , Ueno Naoto T. , Mills Gordon B. , Tripathy Debu , Gonzalez-Angulo Ana M.
Published: April 2023

Effect of targeting PI3K/MET on acini formation and cell invasion
Figure S2 from Cooperative Effect of Oncogenic MET and PIK3CA in an HGF-Dominant Environment in Breast Cancer
Authors: Liu Shuying , Li Shunqiang , Wang Bailiang , Liu Wenbin , Gagea Mihai , Chen Huiqin , Sohn Joohyuk , Parinyanitikul Napa , Primeau Tina , Do Kim-Anh , Vande Woude George F. , Mendelsohn John , Ueno Naoto T. , Mills Gordon B. , Tripathy Debu , Gonzalez-Angulo Ana M.
Published: April 2023

Serum HGF in hHGF Tg/SCID mice
Supplemental Methods and Supplemental Figures S1-S3 from KIT-Dependent and KIT-Independent Genomic Heterogeneity of Resistance in Gastrointestinal Stromal Tumors — TORC1/2 Inhibition as Salvage Strategy
Authors: Mühlenberg Thomas , Ketzer Julia , Heinrich Michael C. , Grunewald Susanne , Marino-Enriquez Adrian , Trautmann Marcel , Hartmann Wolfgang , Wardelmann Eva , Treckmann Jürgen , Worm Karl , Bertram Stefanie , Herold Thomas , Schildhaus Hans-Ulrich , Glimm Hanno , Stenzinger Albrecht , Brors Benedikt , Horak Peter , Hohenberger Peter , Fröhling Stefan , Fletcher Jonathan A. , Bauer Sebastian
Published: April 2023

Supplemental Methods; Supplemental Figure S1: Cancer-related mutations in the DKTK-Master patient cohort; Supplemental Figure S2: T1-PTEN cells were treated with increasing concentrations of approved KIT-inhibitors for 72h and analyzed by SRB assay; Supplemental Figure S3: Dose-combination studies with sapanisertib
Supplemental Methods and Figures 1-5 from Relative Target Affinities of T-Cell–Dependent Bispecific Antibodies Determine Biodistribution in a Solid Tumor Mouse Model
Authors: Mandikian Danielle , Takahashi Nene , Lo Amy A. , Li Ji , Eastham-Anderson Jeffrey , Slaga Dionysos , Ho Jason , Hristopoulos Maria , Clark Robyn , Totpal Klara , Lin Kedan , Joseph Sean B. , Dennis Mark S. , Prabhu Saileta , Junttila Teemu T. , Boswell C. Andrew
Published: April 2023

Supplemental Methods, followed by Supplemental Figures S1, S2, S3, S4 and S5. Supplementary Fig. S1 In vitro binding of TDBs to HER2 and CD3 expressing cell lines. Supplementary Fig. S2 HER2 expression in model cell lines in vitro and tumors in vivo. Supplementary Fig. S3 HER2, CD3Æ� and MECA-32 staining and vascular characterization of HER2 positive and negative tumors. Supplementary Fig. S4 T cell infiltration and CD3 expression in murine CT26 and CT26-HER2 tumors. Supplementary Fig. S5 Pharmacokinetic data from whole blood and cell pellet fractions
Supplementary Table 1 from Comparative Oncology Evaluation of Intravenous Recombinant Oncolytic Vesicular Stomatitis Virus Therapy in Spontaneous Canine Cancer
Authors: Naik Shruthi , Galyon Gina D. , Jenks Nathan J. , Steele Michael B. , Miller Amber C. , Allstadt Sara D. , Suksanpaisan Lukkana , Peng Kah Whye , Federspiel Mark J. , Russell Stephen J. , LeBlanc Amy K.
Published: April 2023

Eligibility criteria to ensure pet dogs meet physical and laboratory candidacy for entry into this clinical trial
Supplementary Figure Legends from Comparative Oncology Evaluation of Intravenous Recombinant Oncolytic Vesicular Stomatitis Virus Therapy in Spontaneous Canine Cancer
Authors: Naik Shruthi , Galyon Gina D. , Jenks Nathan J. , Steele Michael B. , Miller Amber C. , Allstadt Sara D. , Suksanpaisan Lukkana , Peng Kah Whye , Federspiel Mark J. , Russell Stephen J. , LeBlanc Amy K.
Published: April 2023

Supplementary Figure Legends
Supplementary Tables S1-S2 and Supplementary Figures S1-S7 from EZH2 Inhibition by Tazemetostat Results in Altered Dependency on B-cell Activation Signaling in DLBCL
Authors: Brach Dorothy , Johnston-Blackwell Danielle , Drew Allison , Lingaraj Trupti , Motwani Vinny , Warholic Natalie M. , Feldman Igor , Plescia Christopher , Smith Jesse J. , Copeland Robert A. , Keilhack Heike , Chan-Penebre Elayne , Knutson Sarah K. , Ribich Scott A. , Raimondi Alejandra , Thomenius Michael J.
Published: April 2023

Table S1: Conditions and seeding densities of all cell lines used in studies; Table S2. Single agent IC50 values for agents tested for 3 days in 96-well plates as described in Materials and Methods; Figure S1. Tazemetostat dosing reduced H3K27me3 in tumor xenografts and is tolerated by SCID mice; Figure S2: CD40L has little effect on growth of DLBCL cell lines; Figure S3. SU-DHL-5 cells were treated for 4 days with TAZ (0.1 to 1 µM) followed by addition of 500 ng/mL CD40L at the indicated time points (1-60 minutes; Figure S4. An ABC-DLBCL gene signature (1) is up-regulated following tazemetostat treatment in KARPAS-422 (EZH2 mutant GCB), Farage (EZH2 WT GCB), SU-DHL-5 (EZH2 WT GCB), TMD8 (EZH2 WT ABC) and ABC vs. GCB gene signature was applied to RNAseq data from each cell line with and without tazemetostat treatment.; Figure S5: CD40L, but not IL-21 induces PRDM1 in combination with tazemetostat (TAZ); Figure S6. A CD40 responsive gene set (2) is up-regulated following tazemetostat treatment in KARPAS-422 (EZH2 mutant GCB), Farage (EZH2 WT GCB), SU-DHL-5 (EZH2 WT GCB), TMD8 (EZH2 WT ABC) and Basso_CD40¬_SIGNALING_UP gene signature was applied to RNAseq data from each cell line with and without tazemetostat treatment; Figure S7. Model for tazametostat mechanism of action in DLBCL
Supplementary Figure S2 from Glibenclamide Targets Sulfonylurea Receptor 1 to Inhibit p70S6K Activity and Upregulate KLF4 Expression to Suppress Non-Small Cell Lung Carcinoma
Authors: Xu Kexin , Sun Geng , Li Min , Chen Hongling , Zhang Zuhao , Qian Xixi , Li Ping , Xu Lin , Huang Wenbin , Wang Xuerong
Published: April 2023

Supplementary Figure S2 shows SUR1 regulated the growth of NSCLCs, and the expression levels of phosphorylated p70S6K and KLF4.
Supplemental Figure 5 from Nanoparticle-Based Celecoxib and Plumbagin for the Synergistic Treatment of Melanoma
Authors: Gowda Raghavendra , Kardos Gregory , Sharma Arati , Singh Sanjay , Robertson Gavin P.
Published: April 2023

Supplemental Figure 5. H&E Stained sections of organs from mice treated with CelePlum- 777
Supplemental Figure 3 from Nanoparticle-Based Celecoxib and Plumbagin for the Synergistic Treatment of Melanoma
Authors: Gowda Raghavendra , Kardos Gregory , Sharma Arati , Singh Sanjay , Robertson Gavin P.
Published: April 2023

Supplemental Figure 3. Selection of the optimal ratio of Plumbagin and Celecoxib for synergistic killing of melanoma cells
Supplementary Table S2 from Radiation Responses of 2D and 3D Glioblastoma Cells: A Novel, 3D-specific Radioprotective Role of VEGF/Akt Signaling through Functional Activation of NHEJ
Authors: Gomez-Roman Natividad , Chong Ming Y , Chahal Sandeep K. , Caragher Seamus P. , Jackson Mark R. , Stevenson Katrina H. , Dongre Sidhartha A. , Chalmers Anthony J.
Published: April 2023

Tables depicting dose modifying factors (DMF) at surviving fractions of 0.37% and 0.1% survival were calculated for each treatment combination. A, G7, E2 and R10 cells grown in 2D or 3D conditions grown in the presence of VEGF [(+) VEGF], or the absence of VEGF [(-) VEGF] followed by radiation at indicated doses (0-5 Gy). DMF at 0.37 and 0.1 for (+) VEGF compared to (-) VEGF conditions. B, G7, E2 and R10 cells grown in 2D or 3D conditions were treated with DMSO or erlotinib followed by radiation treatment as in A. DMF at 0.37 and 0.1 for erlotinib compared to DMSO conditions. C, G7 and E2 cells were incubated with MK2206, Erlotinib and their combination for 2D conditions or {plus minus}VEGF and MK2206 for 3D conditions and irradiated as in A. DMF calculated for treatments v DMSO for 2D cells; (-) VEGF, (-) VEGF plus MK2206, or (+) VEGF plus MK2206 v (+) VEGF for 3D cells. D, E2 cells were transfected with either siScramble (siScr) or siRNAs against Akt1 and Akt3 for 48 hrs followed by radiation treatment as in A. DMF calculated for siAkt vs siScr. E, Cell lysates from E2 cells transfected with siRNA against DNA-PKcs (siDNAPKcs) or siScr for 48 hours followed by radiation treatment as in A. DMF calculated for treatments v DMSO_siScr.